CD69 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2184946	1.00	5/20
SCHEMBL2217463	1.00	5/20
SCHEMBL2058911	0.45	5/20
SCHEMBL1145948	0.60	4/20
SCHEMBL3729436	0.58	4/20
SCHEMBL1937755	0.55	4/20
SCHEMBL2014943	0.55	4/20
SCHEMBL2059516	0.53	4/20
SCHEMBL2561402	0.47	4/20
SCHEMBL503651	0.45	4/20
SCHEMBL2059331	0.44	4/20
SCHEMBL1525621	0.44	4/20
SCHEMBL830740	0.58	3/20
SCHEMBL326985	0.57	3/20
SCHEMBL1724955	0.53	3/20
SCHEMBL1887188	0.50	3/20
SCHEMBL341114	0.47	3/20
SCHEMBL2059355	0.46	3/20
SCHEMBL902241	0.46	3/20
SCHEMBL2059557	0.44	3/20

Clinical trials — most relevant to CD69 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Application of a TBE-Vaccine in Obese Persons	PHASE4	UNKNOWN
Booster Vaccine for Yellow Fever	PHASE3	UNKNOWN
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts	PHASE2	RECRUITING
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors	PHASE1/PHASE2	COMPLETED
Salt-Sensitivity and Immunity Cell Activation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans	PHASE2	NOT_YET_RECRUITING
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer	PHASE2	RECRUITING
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	PHASE2	COMPLETED
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant	PHASE1	COMPLETED
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma	PHASE1	NOT_YET_RECRUITING
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant	PHASE1	COMPLETED
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy	PHASE1	COMPLETED
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation	PHASE1	COMPLETED
Changes in Natural Immunity in Pregnant Women With Autoimmune Thyroid Disease	nan	NOT_YET_RECRUITING
Adversity and Its Association With the Development and Expression of Rheumatic Diseases	nan	UNKNOWN
T-lymphocytes CD8+/HLA-DR+ and Acute Rejection After Lung Transplantation	nan	UNKNOWN
Study of Product of Conception Derived From Ultrasound-guided Manual Vacuum Aspiration	nan	RECRUITING
Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome	nan	RECRUITING
The Effect of Previous Pregnancies in Patients With Gynecological Neoplasms Treated With PD-1/PD-L1 Inhibitors	nan	NOT_YET_RECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Immunologic Signatures Following Surgery for Pancreatic Cancer	nan	COMPLETED
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation	nan	COMPLETED
Precision Physical Exercise for Personalized Onco-Hematology.	nan	NOT_YET_RECRUITING
ACTH vs Betamethasone in Hospitalized Patients With Acute Gout	nan	UNKNOWN
Fish Oil for HIV-Related Inflamm-aging and Immune Senescence	nan	COMPLETED
PRediction of Outcomes and PERsonalized Radiotherapy by Biomarkers and Functional Imaging	nan	ACTIVE_NOT_RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Sub Populations of Immune Cells in Influenza A and B Patients	nan	UNKNOWN
Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CD69 binder may also engage these)

Protein	Name	Similarity
Q80XD9	—	0.993	Q80XD9 →
Q8C1T8	—	0.992	Q8C1T8 →
A4KWA8	—	0.990	A4KWA8 →
P27811	—	0.990	P27811 →
Q8VI21	—	0.989	Q8VI21 →
Q91V08	—	0.989	Q91V08 →
P37217	—	0.989	P37217 →
O70215	—	0.988	O70215 →
Q99JB4	—	0.987	Q99JB4 →
A4KWA5	—	0.987	A4KWA5 →
Q9WVF9	—	0.986	Q9WVF9 →
Q0H8B9	—	0.985	Q0H8B9 →
P27471	—	0.985	P27471 →
P14371	—	0.985	P14371 →
O54709	—	0.984	O54709 →
Q80ZC8	—	0.984	Q80ZC8 →
KLRK1	NKG2-D type II integral membrane protein (Kil	0.984	landscape →
Q6UXN8	—	0.983	Q6UXN8 →
Q9GLF5	—	0.983	Q9GLF5 →
P27812	—	0.983	P27812 →
Q149M0	—	0.983	Q149M0 →
Q8VD98	—	0.983	Q8VD98 →
Q6UVW9	—	0.982	Q6UVW9 →
P26717	—	0.982	P26717 →
Q925N7	—	0.982	Q925N7 →
Q9P126	—	0.982	Q9P126 →
Q6EIG7	—	0.982	Q6EIG7 →
Q8MI05	—	0.982	Q8MI05 →
Q8MJH1	—	0.982	Q8MJH1 →
P27814	—	0.981	P27814 →